Bioxel Pharma Inc.

Bioxel Pharma Inc.

November 11, 2005 10:34 ET

Bioxel Pharma Completes cGMP Quality Audit for Paclitaxel Used in Medical Device

SAINTE-FOY, QUEBEC--(CCNMatthews - Nov. 11, 2005) - Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer and supplier of taxane APIs and developer of targeted oncology drugs, today announced that it has completed a vendor qualification audit for paclitaxel carried out by a US-based medical device manufacturer. Bioxel has also won an order for paclitaxel to be used by the customer to complete clinical development of its medical device. The companies are in discussions to enter into a long-term paclitaxel supply relationship.

"As with our oncology pharma customers, qualification to supply paclitaxel for medical device comes after a thorough due diligence of Bioxel's supply chain," said Pascal Delmas, President and CEO of Bioxel. "Product quality, timely deliveries and competitive pricing are among the key criteria allowing Bioxel to differentiate itself from competition and continue to win paclitaxel business".

Bioxel manufactures and sells cGMP paclitaxel to medical device, specialty pharmaceutical and generic companies. The Corporation's dedicated cGMP paclitaxel facility has a 120 kilogram annual capacity and is located at an FDA inspected pharmaceutical manufacturing site in California. The paclitaxel product is registered with US, EU and Canadian regulatory authorities, allowing sales into approved formulated products worldwide.


Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis, Alzheimer's disease and cardiovascular disease. The Corporation sells cGMP paclitaxel and develops a portfolio of other generic taxane APIs and taxane-based proprietary products for improved cancer therapy.

This announcement includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. These include risks and uncertainties that could affect Bioxel's products under development such as regulatory factors, technological developments and competitive factors. Achievement of the objectives set forth in this release is subject to these risks and uncertainties. The Corporation's results, or the measures it adopts, could differ materially from those indicated or underlying these statements, or could have an impact on the realization of financial projections.

The TSX Venture Exchange has not reviewed the contents of this press release and accepts no responsibility for the adequacy or the accuracy thereof.

Contact Information

  • Bioxel Pharma Inc.
    Pascal Delmas, Pharm.D, MBA
    President and Chief Executive Officer
    (418) 654-9666